Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. immorist

ImMoRiSt

Immune Monitoring for RIsk STratification in Solid Organ Transplant Recipients

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 ImMoRiSt project word cloud

Explore the words cloud of the ImMoRiSt project. It provides you a very rough idea of what is the project "ImMoRiSt" about.

entry    interferon    right    quantitative    grow    explore    organ    complications    transplant    gamma    every    stimulants    centers    regulatory    triggered    clinically    patient    business    biomarker    ivd    functional    links    lung    immunomonitoring    frequency    lophius    blood    cells    strategy    provides    approval    feasibility    leader    rejection    freedom    ce    improves    highest    recipients    ifn    diagnostic    setting    strength    operate    scan    biosciences    pursued    physicians    suited    sot    marking    heart    cell    detection    market    performed    competitor    transplantation    plan    immunosuppressive    kidney    final    tests    selectively    function    mediated    immune    infections    outcome    obtain    qualitative    liver    release    stimulate    yield    global    germany    parallel    caused    place    uses    switzerland    validation    monitoring    logical    obtaining    drugs    patients    24    transplanted    dosage    clinical    cocktail    relatively    austria    proprietary    validate    firm    solid   

Project "ImMoRiSt" data sheet

The following table provides information about the project.

Coordinator		 LOPHIUS BIOSCIENCES GMBH 

Organization address
address: AM BIOPARK 13
city: REGENSBURG
postcode: 93053
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Germany [DE]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-02-01   to  2016-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    LOPHIUS BIOSCIENCES GMBH DE (REGENSBURG) coordinator 50˙000.00

Map

 Project objective

Every year ~ 40.000 patients throughout the EU are transplanted a new kidney, lung, liver, heart or another organ. The frequency of clinical complications is relatively high because at present there are no diagnostic tests that help physicians to determine the right dosage of immunosuppressive drugs necessary to avoid both organ rejection and clinical complications caused by infections.

Lophius Biosciences GmbH has developed I-Scan, a functional immune monitoring test that within 24 h provides important information on the strength of the immune system in solid organ transplant recipients. I-Scan uses a proprietary cocktail of stimulants that selectively stimulate the clinically relevant immune cells in a patient’s blood sample. The detection of the triggered interferon γ (IFN-γ) release provides a qualitative and quantitative measurement of cell-mediated immune function.

The feasibility study performed during Phase 1 will explore issues related to both, the clinical biomarker validation study and the best market entry strategy. Several objectives are pursued in parallel and encompass: • Setting up the business plan which includes a competitor as well as a freedom-to-operate analysis and a market entry strategy. • Selection of clinical study partners and defining the design of the clinical study, best suited to yield highest clinical evidence • Obtaining regulatory approval for the planned clinical study and setting a strategy to obtain regulatory approval / CE-Marking for final I-Scan products.

Lophius will apply for Phase 2 funding of a clinical study to validate that I-Scan improves the outcome of SOT patients. This study is likely to take place in Germany, Switzerland and Austria where Lophius has already established firm links to transplantation centers. The study is the logical next step to further grow Lophius to become a global leader in the IVD market for immunomonitoring

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IMMORIST" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IMMORIST" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

INTE-AFRICA (2019)

Integrating and decentralising diabetes and hypertension services in Africa

Read More  

AutoCRAT (2020)

Automated Cellular Robot-Assisted Technologies for translation of discovery-led research in Osteoarthritis

Read More  

INADVANCE (2019)

Patient-centred pathways of early palliative care, supportive ecosystems and appraisal standard

Read More